tbuckley/cabot-search huggingface dataset:
Assessment of Intragastric Single-Port Surgery for Gastric Tumors
Authors: Felix Krenzien, Johann Pratschke, Ricardo Zorron
Journal: JAMA Surgery (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
Reply to Whiteman <i>et al</i> .: In-Deed wise to get some sensible sun exposure
Authors: M.F. Holick
Journal: British Journal of Dermatology (2017)

Whiteman, Olsen and Green noted the Felton study (1) was short term and limited by the number of biopsies. What this study demonstrated was that even for only 6 weeks of repeated exposures to sensible suberythemal doses of simulated solar ultraviolet radiation (UVR), there was a marked increase in the skin's defense mechanisms to overcome the damaging effects caused by the DNA absorbing the UVR. Whiteman et al. acknowledge that within 24 hours after the final exposure the levels of photo damage were significantly lower.

This article is protected by copyright. All rights reserved.
Real-world treatment patterns for advanced squamous non-small cell lung cancer in the U.S. Medicare population.
Authors: Ravi K Goyal, Stephen L. Able, Keith L. Davis, Jacqueline Brown, Li Li, James A. Kaye
Journal: Journal of Clinical Oncology (2014)

e17652 Background: Advanced squamous non-small cell lung cancer (NSCLC) represents approximately 22% of all lung cancer cases in the US. Although prognosis is generally poor, treatment selection plays an important role in prolonging survival for these patients. In this study, we described treatment patterns observed in real-world clinical settings for US Medicare enrollees diagnosed with advanced squamous NSCLC. Methods: A retrospective analysis was conducted using the SEER-Medicare linked database for patients with advanced squamous NSCLC aged ≥65 years and diagnosed during 2001-2009. Post-diagnosis prevalence of broad categories of cancer-directed treatment approaches (surgery, radiation, chemotherapy, biologic therapy) was analyzed. Among patients initiating a systemic therapy regimen, detailed characteristics of the most frequently observed first-, second-, and third-line regimens were assessed. Results: A total of 17,133 patients were identified for study inclusion (median age 75, 62% male). Of the total sample, 56% received radiation, 45% received chemotherapy, 19% received surgery, and 1% received biologic therapy. Overall, approximately 72% of the total sample received ≥1 cancer-directed treatment. Among patients initiating a first-line systemic treatment (n=7,029), the most common regimen was, by far, carboplatin plus paclitaxel combination therapy (46%); the next most common first-line regimen (10% of patients) was carboplatin plus gemcitabine. Of all first-line systemic regimen initiators, 48% subsequently initiated a second-line regimen; 24% went on to initiate a third-line regimen. Gemcitabine monotherapy was the most frequently used regimen in second- (16%) and third-line settings (16%). Docetaxel monotherapy was second most common second-line regimen (13%). Conclusions: Consistent with current National Cancer Center Network (NCCN) treatment guidelines, platinum-based doublet chemotherapy was the most common first-line treatment among chemotherapy-treated patients in the real-world settings captured in our study. Second-line treatment selections were more varied and not necessarily consistent with current NCCN recommendations.
Risk of major birth defects rises with severity of mother’s overweight
Authors: Zosia Kmietowicz
Journal: BMJ (2017)

The risk of major congenital malformations during the first year of life increases with a mother’s weight, from 5% higher in women who are overweight to 37% higher in women with the most severe obesity, a large cohort study in The BMJ has found.1

The findings prompted researchers to advise doctors to encourage women who are planning to become pregnant to establish a normal weight before conceiving.

Maternal obesity is already known to increase the risk of congenital malformations, but it was not clear whether overweight mothers all carry similar risks or whether these risks increase with …
Abstract 237: Antioxidant and Ryanodine Receptor Stabilizing Therapy Prevent Statin-Induced Contractile Dysfunction in a Tissue-Engineered Skeletal Muscle Model
Authors: Malte Tiburcy, Guenther Engel, Sonka J Sanders, Wolfram H Zimmermann
Journal: Circulation Research (2012)

Rationale: Skeletal muscle toxicity of HMG-CoA-reductase inhibitors (statins) ranges from reversible myalgia to irreversible rhabdomyolysis. The underlying molecular mechanisms are not well defined. Tissue engineering models may help to gain insight into these clinically limiting pathologies. Objective: Here we aimed to model a phenotype of reversible myalgia in vitro to decipher mechanisms that contribute to the early stage of statin toxicity. Methods and Results: Engineered skeletal muscle (ESM) was generated from rat myoblasts, matrigel, and collagen. Isometrically suspended ESM developed 1.2±0.1 mN force under tetanic field stimulation (80 Hz; 200 mA; n=25). Exposure of ESM to statins for 5 days resulted in a loss of force and increased fatiguability in a concentration dependent manner. Cerivastatin was identified as the most potent statin with respect to muscle toxicity with a TC50 (=50% force reduction) of 0.02 µmol/L (n=25/group). Interestingly, at low cerivastatin concentration (0.01 µmol/L) contractile force of ESM was impaired without obvious signs for structural muscle damage (sarcomeric actin content, CK activity unchanged, n=4). Importantly, ESM dysfunction was fully reversible if challenged with TC50 statin concentrations (n=12-14/group). We reasoned that contractile dysfunction with increased fatiguability resulted from calcium leak via the ryanodine receptor. To test this hypothesis we co-administered S107 and observed a concentration-dependent inhibition of statin-induced force reduction (n=12) and calpain activitiy (a calcium-dependent protease, n=4-6). We further argued that RYR destabilization may have been caused by reactive nitrogen (RNS) and/or reactive oxygen species (ROS). Interestingly, the antioxidant N-acetyl cysteine (1 mmol/L, n=3/group), but not L-NAME (10 mmol/L; NO-synthase inhibition, n=6-12/group) prevented contractile dysfunction. Conclusion: We utilized a novel tissue engineered skeletal muscle model to decipher mechanisms of statin-induced muscle toxicity and provide evidence for a central role of ryanodine receptor leak, possibly caused by oxidative damage. Our data suggest that antioxidant and RYR-stabilizing approaches may be useful in counteracting statin myopathy.
Decitabine (DAC) in Combination with Donor Lymphocyte Infusions (DLIs) Can Induce Remissions of Overt Aml Relapses after Allogeneic Transplantation
Authors: Sebastian Sommer, Rainer Claus, Hartmut Bertz, Ralph Wäsch, Reinhard Marks, Robert Zeiser, Ljudmila Bogatyrova, Jürgen Finke, Michael Lübbert
Journal: Blood (2016)
When Somatic Mutations Are Associated With a Higher Aggressive Behavior—A Story of Announced Evidence—Reply
Authors: Rengyun Liu, Mingzhao Xing
Journal: JAMA Oncology (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
Eosinophils display and activated phenotype in clinically active inflammatory bowel disease
Authors: CM Smyth, S Woods, A O'Grady, GJ Gleich, EW Kay, FE Murray, RW Costello
Journal: Endoscopy (2005)

Aim: In IBD eosinophils may lead to symptoms through the release of toxic cationic proteins, or contribute to remodelling through the release of TGF-beta. The aim of this study was to evaluate the phenotype of eosinophils in large bowel mucosa of patients with (1) symptomatic active disease that was responsive to treatment, [n=11], (2) subjects refractory to treatment, [n=15], and (3) control non-affected subjects, [n=10]. Eosinophil numbers, release of cationic major basic protein (MBP) and expression of TGF-beta were determined.
Abstract 240: Strategic Distribution of the Mitochondrial Ca2+ Uniporter in Cardiac Mitochondria
Authors: Sergio de la Fuente, Caitlin Vail, Elorm J Agra, Kira Holmstrom, Junhui Sun, Jyotsna Mishra, Toren Finkel, Elizabeth Murphy, Shey-Shing Sheu, Gyorgy Csordas
Journal: Circulation Research (2015)

Propagation of SR-derived Ca2+ signals to the mitochondrial matrix is an important tuning tool of cardiac energy metabolism (excitation-bioenergetics coupling). Effective activation of the low-affinity mitochondrial Ca2+ uniporter (mtCU) is supported by high [Ca2+] nanodomains where SR cisternae are tethered to mitochondria. Cardiac mitochondria have large inner membrane (IMM) surface with extensive cristae folding. However, recent comparative patch clamp studies found cardiac mtCU current density extremely low. We hypothesized that efficient excitation-bioenergetics coupling would require strategic positioning of the mtCU. We thus analyzed the distribution of mtCU’s pore protein, MCU in rat and mouse cardiomyocytes and cardiac membrane fractions. Immunofluorescence (IF) using the commercial Sigma antibody showed significant non-mitochondrial (nuclear, cyto/sarcoplasmic) crossreactions as verified in MCU-KO MEFs and cardiomyocytes. To isolate mitochondrial labeling, we performed IF of isolated mitochondria (mtIF) and immunogold electron microscopy of freshly isolated cardiomyocytes. mtIF showed ~50% of MCU-positive structures colocalized with RyR2, in line with a location preference to SR-mitochondria associations. This distribution bias was also reflected in the immunogold TEM analysis. Moreover, WB showed both MCU and calsequestrin being enriched in the same sub-mitochondrial membrane fraction separated on sucrose gradient. The prevalence of MCU and even more the essential MCU regulator (EMRE) was higher in the mitochondria “contaminating” the heavy SR (SR-associated mito membranes) than in the crude mitochondrial fraction. [Ca2+] activation of mitochondrial Ca2+ uptake at similar IMM potentials was as effective in suspensions of SR-associated mito membranes as in the crude mitochondrial fraction. Collectively, our data suggest a location bias of the functionally mandatory mtCU channel components MCU and EMRE toward SR-mitochondrial associations. As the bias is much stronger for EMRE, the component that is required for MCU to function as a channel, it raises the possibility that EMRE availability may be a physiological limiting factor in regional mtCU activity in the cardiac muscle mitochondria.
Second- or third-line nivolumab (Nivo) versus nivo plus ipilimumab (Ipi) in malignant pleural mesothelioma (MPM) patients: Results of the IFCT-1501 MAPS2 randomized phase II trial.
Authors: Arnaud Scherpereel, Julien Mazieres, Laurent Greillier, Pascal Dô, Olivier Bylicki, Isabelle Monnet, Romain Corre, Clarisse Audigier-Valette, Myriam Locatelli-Sanchez, Olivier Molinier, Luc Thiberville, Thierry Urban, Catherine Ligeza-poisson, David Planchard, Elodie Amour, Franck Morin, Denis Moro-Sibilot, Gerard Zalcman
Journal: Journal of Clinical Oncology (2017)

LBA8507 Background: To date, no treatment is recommended in MPM pts progressing after 1 st -line pemetrexed-platinum doublet. Disease control rate (DCR) is &lt;30% with all drugs tested in 2 nd -line setting. Preliminary results suggested possible activity of anti-PD-1 mAb in 2 nd /3 rd- line, opposed to single agent anti-CTLA-4 mAb. Therefore anti-PD1 mAb efficacy deserves confirmation, and anti-PD-1 + anti-CTLA-4 combination value is currently unknown in MPM. Methods: In this multicenter randomized non comparative phase 2 trial, eligible pts had age&gt;18, PS 0-1, histologically proven MPM relapsing after 1 or 2 prior lines including pemetrexed/platinum doublet, measurable disease. Randomized pts (1:1) received Nivo 3 mg/kg q2w, or Nivo 3 mg/kg q2w + Ipi 1 mg/kg q6w, until progression or unacceptable toxicity. Primary endpoint was DCR at 12 weeks with a blinded independent central review (BICR). 114 patients were to be randomized (with 108 eligible), with one-step Fleming procedure, H0 P&lt;20% vs H1 P&gt;40%, with 95% power, 5% one-sided a-risk: ≥17 failure-free pts had to be observed at 12 weeks in either arm, to conclude to the activity of the corresponding regimen. Results: From March to August 2016, 125 pts were enrolled in 21 centers. Males: 80%, median age: 71.8 years (range 32.5-88.1), PS 1: 62.4%, epithelioid 83.2%, 1 previous line: 69.6%; 70% of pts received ≥ 3 cycles of either treatment. Twelve weeks-DCR assessed by BICR in the first 108 eligible pts was 42.6% [IC95%: 29.4-55.8%] with Nivo (n=23/54), and 51.9% [38.5-65.2%] with Nivo+Ipi (n=28/54). ORR was 16.7% [6.7%-26.6%] with Nivo (n=9/54), and 25.9% [14.2-37.6%] with Nivo+Ipi (n=14/54). All grade/G3-4 toxicities were slightly increased in the combo arm (86.9%/16.4%) vs Nivo alone (77.8%/9.5%); 3 treatment-related deaths were observed in the combo arm (1 metabolic encephalopathy, 1 fulminant hepatitis, 1 acute renal failure). Full QoL, PFS and OS data will be presented at 2017 ASCO meeting. Conclusions: Both Nivo and Nivo+Ipi arms reached their endpoint in 2 nd /3 rd- line MPM pts, suggesting that immunotherapy may provide new options for these pts. Clinical trial information: NCT02716272.
Is the atopic march related to confounding by genetics and early‐life environment? A systematic review of sibship and twin data
Authors: S. J. Khan, S. C. Dharmage, M. C. Matheson, L. C. Gurrin
Journal: Allergy (2017)

Abstract A popular hypothesis known as the atopic march proposes a set of sequential allergy and respiratory disorders in early childhood contributes enormously to the burden of disease in developed countries. Although the concept of the atopic march has been refined and strengthened by many cross‐sectional and longitudinal studies linking eczema as the initial manifestation with progression to hay fever and then asthma, there is yet no definitive proof that the atopic march is the primary causal factor in childhood allergic disease. This debate is mainly related to the controversy around potential confounding of these associations by genetic and environmental factors. Family studies are ideally suited to unravelling the role of these factors. While multiple reviews have synthesized evidence from studies investigating this question, no review to date has explored specific evidence generated by twin and sibling studies to understand the aetiology of atopic march diseases. Our aim was to conduct a systematic review of twin and sibling studies that examine the allergic phenotypes that form the atopic march, to determine whether such analyses of data from these studies attempt to control for the effect confounding by shared factors, and to report estimates of the magnitude of associations between multiple phenotypes. Our review suggests that (1) genetics play a bigger role predisposing eczema to hay fever and eczema to asthma than environmental factors, and (2) the link between eczema and asthma and hay fever is independent of shared early‐life environmental factors.
Arl13b Promotes Gastric Tumorigenesis by Regulating Smo Trafficking and Activation of the Hedgehog Signaling Pathway
Authors: Jia Shao, Linlin Xu, Limin Chen, Quqin Lu, Xinsheng Xie, Wei Shi, Huanting Xiong, Chao Shi, Xuan Huang, Jinhong Mei, Hai Rao, Hua Lu, Nonghua Lu, Shiwen Luo
Journal: Cancer Research (2017)

Inhibitors of the Hedgehog (Hh) pathway transducer Smoothened (Smo) have been approved for cancer treatment, but Smo mutations often lead to tumor resistance and it remains unclear how Smo is regulated. In this study, we identified the small GTPase Arl13b as a novel partner and regulator of Smo. Arl13b regulated Smo stability, trafficking, and localization, which are each crucial for Hh signaling. In gastric cancer cells, Arl13b stimulated proliferation, migration, and invasion
The Impact of NFAT Inhibition on Neutrophil Effector Functions in Patients after Allogeneic Hematopoietic Stem Cell Transplantation and on Neutrophil Antifungal Defense and Myelopoiesis in Cyclosporin Α Treated and NFATc1LysM Mice
Authors: Daniel Teschner, Katharina Plein, Christian Michel, Steve Pruefer, Matthias Bros, Eva Maria Wagner, Matthias Theobald, Hansjoerg Schild, Markus Radsak
Journal: Blood (2016)
In VTE, extending anticoagulation with rivaroxaban vs aspirin reduced recurrence without increasing bleeding
Authors: Andrew Dunn
Journal: Annals of Internal Medicine (2017)

ACP Journal Club20 June 2017In VTE, extending anticoagulation with rivaroxaban vs aspirin reduced recurrence without increasing bleedingAndrew Dunn, MD, MPH, FACP, SFHMAndrew Dunn, MD, MPH, FACP, SFHMMount Sinai Health System–New York, New York, New York, USA (A.D.)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/ACPJC-2017-166-12-065 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Source CitationWeitz JI, Lensing AW, Prins MH, et al; EINSTEIN CHOICE Investigators. Rivaroxaban or aspirin for extended treatment of venous thromboembolism. N Engl J Med. 2017;376:1211-22. https://pubmed.ncbi.nlm.nih.gov/28316279Clinical Impact RatingsGIM/FP/GP: Hematology: References1 Kearon C, Akl EA, Ornelas J, et al. Antithrombotic therapy for VTE disease: CHEST guideline and Expert Panel report. Chest. 2016;149:315-52. [PMID: 26867832] Google Scholar2 Agnelli G, Buller HR, Cohen A, et al; AMPLIFY-EXT Investigators. Apixaban for extended treatment of venous thromboembolism. N Engl J Med. 2013;368:699-708. [PMID: 23216615] Google Scholar3 EINSTEIN Investigators, Bauersachs R, Berkowitz SD, et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010;363:2499-510. [PMID: 21128814] Google Scholar Author, Article, and Disclosure InformationAffiliations: Mount Sinai Health System–New York, New York, New York, USA (A.D.)This article was published at Annals.org on 6 June 2017. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 20 June 2017Volume 166, Issue 12Page: JC65KeywordsAnticoagulant therapyAnticoagulantsAntiplatelet therapyApixabanAspirinHemorrhageIntent to treat analysisPulmonary embolismSafetyVenous thromboembolism ePublished: 20 June 2017 Issue Published: 20 June 2017 Copyright & PermissionsCopyright © 2017 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Red Blood Cell Invasion by the Malaria Parasite Is Coordinated by the PfAP2-I Transcription Factor
Authors: Joana Mendonca Santos, Gabrielle Josling, Philipp Ross, Preeti Joshi, Lindsey Orchard, Tracey Campbell, Ariel Schieler, Ileana M. Cristea, Manuel Llinás
Journal: Cell Host & Microbe (2017)
Резистин як маркер порушення функції печінки при поєднаному перебігу неалкогольної жирової хвороби печінки та цукрового діабету 2-го типу
Authors: L.V. Zhuravliova, O.V. Ohnieva
Journal: GASTROENTEROLOGY (2020)

Мета роботи — оцінити взаємозв’язок резистину з показниками функціонального стану печінки у хворих на неалкогольну жирову хворобу печінки (НАЖХП), цукровий діабет (ЦД) 2-го типу та при їх поєднанні. Матеріали та методи. Було обстежено 110 хворих, серед них 20 хворих на НАЖХП, 20 хворих на ЦД 2-го типу та 70 хворих із коморбідною патологією (НАЖХП + ЦД 2-го типу), які були розподілені на 2 підгрупи — 20 хворих із нормальною масою тіла і 50 хворих з ожирінням. Контрольну групу становили 20 практично здорових осіб. Було проведено комплексне клінічне, лабораторне (з визначенням показників білкового, пігментного, ферментного та вуглеводного обміну, рівня резистину), інструментальне (ультразвукове дослідження печінки та біопсія печінки (у 8 хворих)) обстеження. Результати. Відзначено вірогідне збільшення плазмового рівня резистину у хворих із коморбідною патологією. Встановлено вірогідні зв’язки рівня резистину з показниками функціонального стану печінки у цих хворих. Висновок. У хворих на НАЖХП, ЦД 2-го типу та при їх поєднанні, особливо з супутнім ожирінням, спостерігається дисбаланс продуктів жирової тканини, ознакою якого є збільшення рівня резистину. Взаємозв’язки між резистином і показниками функціонального стану печінки переважно в підгрупі з коморбідною патологією та ожирінням дають підстави вважати, що при ожирінні активуються і поглиблюються гормонально-метаболічні порушення, що негативно впливають на функцію печінки.